Cargando…

Myelomatous effusion with poor response to chemotherapy.

While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Y. M., Lee, K. K., Oh, H. S., Park, S. K., Won, J. H., Hong, D. S., Park, H. S., Park, J. S., Lee, D. W.
Formato: Texto
Lenguaje:English
Publicado: Korean Academy of Medical Sciences 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054621/
https://www.ncbi.nlm.nih.gov/pubmed/10803706
_version_ 1782199990328754176
author Kim, Y. M.
Lee, K. K.
Oh, H. S.
Park, S. K.
Won, J. H.
Hong, D. S.
Park, H. S.
Park, J. S.
Lee, D. W.
author_facet Kim, Y. M.
Lee, K. K.
Oh, H. S.
Park, S. K.
Won, J. H.
Hong, D. S.
Park, H. S.
Park, J. S.
Lee, D. W.
author_sort Kim, Y. M.
collection PubMed
description While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion.
format Text
id pubmed-3054621
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-30546212011-03-15 Myelomatous effusion with poor response to chemotherapy. Kim, Y. M. Lee, K. K. Oh, H. S. Park, S. K. Won, J. H. Hong, D. S. Park, H. S. Park, J. S. Lee, D. W. J Korean Med Sci Research Article While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare. We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion. The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid. Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP). Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed. We reviewed the clinical feature of this case and literature concerning myelomatous pleural effusion. Korean Academy of Medical Sciences 2000-04 /pmc/articles/PMC3054621/ /pubmed/10803706 Text en
spellingShingle Research Article
Kim, Y. M.
Lee, K. K.
Oh, H. S.
Park, S. K.
Won, J. H.
Hong, D. S.
Park, H. S.
Park, J. S.
Lee, D. W.
Myelomatous effusion with poor response to chemotherapy.
title Myelomatous effusion with poor response to chemotherapy.
title_full Myelomatous effusion with poor response to chemotherapy.
title_fullStr Myelomatous effusion with poor response to chemotherapy.
title_full_unstemmed Myelomatous effusion with poor response to chemotherapy.
title_short Myelomatous effusion with poor response to chemotherapy.
title_sort myelomatous effusion with poor response to chemotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054621/
https://www.ncbi.nlm.nih.gov/pubmed/10803706
work_keys_str_mv AT kimym myelomatouseffusionwithpoorresponsetochemotherapy
AT leekk myelomatouseffusionwithpoorresponsetochemotherapy
AT ohhs myelomatouseffusionwithpoorresponsetochemotherapy
AT parksk myelomatouseffusionwithpoorresponsetochemotherapy
AT wonjh myelomatouseffusionwithpoorresponsetochemotherapy
AT hongds myelomatouseffusionwithpoorresponsetochemotherapy
AT parkhs myelomatouseffusionwithpoorresponsetochemotherapy
AT parkjs myelomatouseffusionwithpoorresponsetochemotherapy
AT leedw myelomatouseffusionwithpoorresponsetochemotherapy